Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 198 209 Sepideh Hassanpour Khodaei Department of Dentistry, Eastern Mediterranean University (EMU) Famagusta, North Cyprus Mersin 10, Turkey Leila Roshangar Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Jafar Soleimani Rad Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Shahnaz Sabetkam Department of Anatomy, Faculty of Medicine, University of Kyrenia, Mersin 10, Kyrenia, Turkey 2024 08 14 2025 05 03 Background: The Wound healing process, as a coordinated physiological mechanism, is a critical subject in medicine. The slow healing and scar formation associated with numerous conventional therapies have led researchers to seek new and more effective therapeutics.  This study evaluated the effects of Mummy material, Wharton Jelly Stem Cells (WJSCs), and Adipocyte Stem cells (ASCs) on the fibroblast migration and proliferation. Materials and Methods: It was demonstrated that fibroblast cells could attach to three-dimensional (3D) scaffolds in the mentioned microenvironment. ASCs and WJSCs were enriched from human adipose tissue and women undergoing cesarean section, respectively. The proliferation rate, migration, expression of fibronectin, collagen I, III, and cell adhesion on PCL scaffold in the presence of mummy material were investigated. Results: The results emphasized the importance of Mummy material, ASCs, and WJSCs in the migration and proliferation of fibroblast cells. The presence of the aforementioned components and cells enhanced the expression of fibronectin (FN1) and collagen types I and III. Additionally, the mummy material was found to promote the proliferation of ADSCs and WJSCs seeded on the PCL scaffold. Together, these findings demonstrate a valuable in vitro technique for studying the healing process. Conclusion: As a result, the potential for using Mummy material and stem cell-based therapeutics in wound healing is exciting. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2300 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2300/1086

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 237 247 Alireza Sadeghi Moghaddam Bijari Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran Mahdi Alijanianzadeh Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran Hoda Keshmiri Neghab Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran Mohammad Hasan Soheilifar Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran 2024 08 12 2025 05 03 The skin is a vital organ that plays a crucial role in healing disruptions and abnormalities. Cutaneous wound healing faces some obstacles in certain abnormalities, including in diabetic patients. Various therapeutic approaches have been explored to enhance healing and restore skin integrity. In recent years, exosomes have been introduced as a new cell-free therapy for wound healing. They are defined as naturally secreted nanovesicles released from most cell types into the extracellular space that can impact many targeted cells. In contrast to previous methods, exosomes have a longer half-life in target tissue and exert a more lasting effect. They also have fewer side effects thanks to their natural biological source. Exosomes derived from mesenchymal stem cells (MSCs) have been widely studied for their therapeutic potential, but those from other cell types, such as fibroblasts, remain less explored. This review aims to comprehensively evaluate existing research on the wound-healing effects of fibroblast-derived exosomes (FB-EXOs), highlighting their potential as a novel treatment strategy. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2299 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2299/1090

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 286 290 EN Atefeh Rezaee Ahvaz Jundishapur University of Medical Sciences, Thalassemia and Hemoglobinopathy Research Centre, Health Research Institute, Ahvaz, Iran Tina Vosoughi Ahvaz Jundishapur University of Medical Sciences, Thalassemia and Hemoglobinopathy Research Centre, Health Research Institute, Ahvaz, Iran Mehran Hosseinzadeh Ahvaz Jundishapur University of Medical Sciences, Thalassemia and Hemoglobinopathy Research Centre, Health Research Institute, Ahvaz, Iran Mohammad Hossein Rastegar Ahvaz Jundishapur University of Medical Sciences, Thalassemia and Hemoglobinopathy Research Centre, Health Research Institute, Ahvaz, Iran 2024 04 16 2025 05 03 Sweet's syndrome is a rare dermatological condition characterized by a constellation of clinical features, including fever, neutrophilic leukocytosis, painful skin plaques, and dermal neutrophil infiltration. Various etiologies have been documented, encompassing both underlying diseases and pharmacological agents. We present a case involving a 35-year-old female patient who exhibited fever and progressive cutaneous lesions manifesting as a painful erythematous rash on the limbs and trunk. Initially misdiagnosed as seronegative lupus erythematosus, her condition did not improve. A skin biopsy revealed significant neutrophilic infiltration, and she subsequently developed leukocytosis, leading to a diagnosis of acute leukemia upon bone marrow examination. The patient was treated with chemotherapy, resulting in a relative improvement of her skin lesions. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2223 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2223/1093

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 210 214 Awad-Elkareem Abass Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia Isra Babiker Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Alaa Mohmmed Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Remaz Hamza Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Salma Albashir Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Ohood Osman Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Safa Abbas Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan Amna Idris Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan 2024 03 06 2024 05 30 Background: The expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in B-cell chronic lymphoproliferative disorders (B-CLPDs) can provide valuable prognostic information and assist in assessing minimal bone marrow (BM) infiltration. This study aimed to detect BCL-2 expression in B-CLPDs and correlate the findings with various clinicobiologic factors. Materials and Methods: Immunocytochemical staining was performed on mononuclear cell smears from 46 Sudanese patients, including 25 with B-cell chronic lymphocytic leukaemia (B-CLL) and 21 with B-cell non-Hodgkin’s lymphomas (B-NHL), who were enrolled during their visit to the Radiation and Isotope Centre and Fedail Hospital, Khartoum. Diagnosis was based on clinical examination, morphology, and immunophenotyping. Results: Among the 46 B-CLPD cases, BCL-2 expression was identified in 13 (28.2%), including 8/25 (32%) cases with B-CLL and 5/21 (23.8%) with B-NHL. No statistically significant associations were found between BCL-2 expression and age, sex, total white blood cell count, disease stage, and serum lactate dehydrogenase levels (all P>0.05). However, BM involvement was significantly associated with BCL-2 expression (P=0.02). Conclusion: The immunocytochemical staining method effectively detects BCL-2 protein in B-CLPDs, even in cases with minimal BM infiltration, thereby facilitating the correlation of this protein’s expression with morphological and other clinicobiologic features. By combining cytologic morphology with immunocytochemistry, this technique enables earlier and more accessible evaluation of BM involvement. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2193 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2193/1087

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 248 260 I Made Adi Narendranatha Komara Department of Internal Medicine, Faculty of Medicine, Udayana University/Central General Hospital Prof. Dr. I.G.N.G Ngoerah Denpasar, Bali, Indonesia Ketut Suega Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia Ni Made Renny Anggreni Rena Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia I Wayan Losen Adnyana Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia 2024 08 08 2024 12 18 Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. This study aims to conduct a five-year update on induction chemotherapy's efficacy, safety, and prognostic value in patients with AML. Based on the PRISMA 2020 guidelines, a systematic search was performed on online databases for relevant studies on complete remission with incomplete hematologic response (CRi), complete remission (CR), adverse events, and overall survival. The articles obtained were observational studies that met the inclusion and exclusion criteria. The quality of the studies was assessed using the Revised Cochrane’s risk-of-bias tool. The analysis was conducted using Review Manager 5.4 and R Statistical Software 3.3. Thirteen clinical trial studies, involving 1,863 participants, were included in this survey. Based on the analysis, the CRi and CR levels, where each was obtained as a whole at 9% (random effect; 95%CI 6-13%; heterogeneity; https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2294 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2294/1091

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 291 295 Vishnu Sharma Department of General Medicine, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India Sidharth Mahajan Government Medical College, Amritsar, India Vansh Bagrodia Department of General Medicine, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India Jahanvi Grover PGIMS, Rohtak, India Vaibhav Oberoi Government Medical College, Amritsar, India 2024 03 03 2024 05 29 This case study outlines the complex treatment journey of a 53-year-old male diagnosed with Chronic Myeloid Leukemia (CML). Despite initial therapy with Imatinib and a subsequent switch to Dasatinib and then Bosutinib due to treatment resistance and adverse effects, the patient experienced multiple unexpected complications, including bilateral pleural effusions, pulmonary arterial hypertension, renal impairment, and neurological symptoms. Bosutinib was identified as the likely cause, leading to its discontinuation and transition to Nilotinib, which resulted in a sustained molecular response without further adverse events. Through this case report and literature review, we aim to expand the dimensions of the toxicity profile of bosutinib.                                                           https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2187 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2187/1094

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 215 222 Elamathi Manoharan Department of Hematology, Apollo Hospitals, Chennai, India Thulasi Ramalingam Department of Hematology, Apollo Hospitals, Chennai, India Revathy Raj Department of Paediatric Hematology and Oncology, Apollo Hospitals, Chennai, India Lakshman Vaidhyanathan Department of Hematology, Apollo Hospitals, Chennai, India 2024 05 09 2025 06 02 Background: This study aimed to evaluate the rate of neutrophil and platelet engraftment in pediatric hematopoietic stem cell transplant (HSCT) patients. Additionally, it sought to assess whether engraftment kinetics were influenced by CD34+ cell dose, CD3+ cell dose in T cell-replete transplants with post-transplant cyclophosphamide (PTCy), and the type of stem cell transplantation. Materials and Methods: The study included 60 pediatric patients undergoing hematopoietic stem cell transplantation between August 2023 and January 2024. Flow cytometry was used to quantify CD34+ cells. A peripheral smear and the haematology analyzer were used to measure the platelet count and neutrophils munosuppression. Nestin staining revealed hypertrophic astrocytes forming patches about blood vessels with positive cytoplasmic staining in endothelium and pericytes (5-10% of the intra-tumor arterioles). These findings were seen in both B and T lymphomas. OCT4 nuclear expression was only observed in five large B-cell lymphomas and seemed to have a relationship with mitoses/HPF (high power field). Conclusion: The novel finding of endothelial, pericytes and hypertrophic astrocytes staining with nestin, points to the involvement of stem cells promoting angiogenesis as a result of a dialogue between neoplastic cells and vascular stem cells. OCT4 expression seems to have a relationship with cell proliferation whose clinical significance should be investigated in prospective studies. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2069 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2069/1065

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 50 59 EN Hessyani Raranta Department of Clinical Laboratory, Prof. Dr. R. D. Kandou Manado Hospital, Jl. Raya Tanawangko No.56, Malalayang Satu Barat, Malalayang, Manado, North Sulawesi, Indonesia 95262 Purwanto Adipireno Department of Clinical Pathology, Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia Indranila Samsuria Department of Clinical Pathology, Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia 2023 08 11 2024 08 21 RET-He is a cost-effective parameter to assess iron status in CKD, but further research is necessary to assess its correlation with existing parameters. This study attempted to investigate the correlation between RET-He, iron status, and erythrocyte indices among CKD patients. Materials and Methods: A cross-sectional study involving 110 CKD patients who underwent routine hematology and iron profile tests (serum iron/SI, total iron binding capacity/TIBC, transferrin saturation/TSAT, and ferritin). RET-He was then measured using a Sysmex XN-1000 hematology analyzer. Statistical tests were used to define the correlation between RET-He), iron status, and erythrocyte indices. Results: There was a significant positive correlation between RET-He and SI (r = 0.349; p = 0.000), TSAT (r = 0.393; p = 0.000), and ferritin (r = 0.279; p = 0.003). Among CKD patients with excess iron levels, there was a moderate correlation between RET-He and TSAT (r = 0.404; p = 0.000). Conclusion: The study found a significant correlation between RET-He levels and iron status markers in CKD patients. RET-He is recommended as an additional parameter to assess iron status and as an additional method to estimate TSAT and ferritin levels, especially in settings where chemistry analyzers are unavailable. Further research is required to establish RET-He cut-off values for identifying excessive iron levels in CKD patients.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2072 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2072/1066

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 60 68 Tanaz Bahri 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Mojtaba Azari Alanjeq Urmia University of Medical Sciences, urmiah, Iran Mohammad Vaezi 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ghasem Janbabaei Mollah 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Fatemeh Tajik Rostami 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Maryam Barkhordar 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Morteza Azari Alanjeq Urmia University of Medical Sciences, Urmiah, Iran Mohammad Biglari 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Sahar Tavakoli Shiraji 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Soroush Rad 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Davoud Babakhani 1) Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammadreza Rostami 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Seied Asadollah Mousavi 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Hosein Kamranzadeh Foumani 1) Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Cancer and Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran 2024 05 28 2024 10 14 for acute leukemia, though outcomes in older patients remain suboptimal due to higher non-relapse mortality (NRM) and relapse rates. Innovations in conditioning regimens and supportive care have made HSCT accessible to patients over 50, but age-related disparities in outcomes persist. Materials and Methods: This 10-year retrospective cohort study reviewed all patients who underwent first-time allogeneic HSCT for acute leukemia. Patients were stratified by age at HSCT (≥ 50 years and < 50 years), and outcomes were assessed for overall survival (OS), disease-free survival (DFS), NRM, and relapse incidence (RI). Results: Of the 1199 patients, 152 were 50 years or older. Five-year OS rates were markedly lower in patients ≥ 50 years compared to younger patients (48.70% vs. 59.35%; P= 0.024 for AML and 23.60% vs. 41.96%; P= 0.025 for ALL). Moreover, older patients demonstrated significantly higher NRM rates (35.95% vs. 23.53%; P= 0.045 for AML and 78.14% vs. 26.76%; P= 0.005 for ALL) and a notably increased incidence of grade III-IV acute graft-versus-host disease (aGVHD). Interestingly, no significant differences were observed between the two age groups regarding DFS rates and RI. Conclusion: Older acute leukemia patients undergoing allogeneic HSCT face significant challenges, including elevated NRM and GVHD rates. While relapse rates were comparable, survival outcomes favored the younger cohort. These findings emphasize the need for age-adapted transplantation strategies, using reduced-intensity conditioning (RIC) regimens and further research to refine risk stratification and improve management approaches for older patients. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2252 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2252/1067

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2023 08 21 69 74 Saeed Nateghi Department of Cardiology, Baharloo Hospital, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Aziz Rasooli Department of Emergency Medicine, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Leila Moadabshoar Head of Prevention and Cancer Control Group, Ministry of Health and Medical Education, Tehran, Iran Zahra Panahi 4Department of Perinatology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Mohammadreza Rostami 1)Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran 2)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2023 06 26 2023 07 18 Hematopoietic stem cell transplantation (HSCT) is considered a potentially curative treatment for several malignant and non-malignant hematologic disorders including transfusion-dependent thalassemia (TDT). However, HSCT is associated with short-term and long-term complications. One of the recognized causes of morbidity and mortality in TDT patients is heart-related complications. Additionally, cardiac involvement is likely to be more common in patients who proceed to HSCT. So the risks of cardiac complications should be carefully weighed against the advantages of the primary disease cure. This review aims to discuss the cardiac considerations that should be kept in mind in TDT patients going through the path of HSCT. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2057 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2057/1072

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 75 80 Saeid Anvari 1)Department of Hematology and Medical Oncology, Guilan University of Medical Sciences, Rasht, Iran 2)Regenerative Medicine, Organ Procurement and Transplantation Multi-Disciplinary Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran Amirhossein Larijani 1)Regenerative Medicine, Organ Procurement and Transplantation Multi-Disciplinary Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran 2)Student Research Committee, Guilan University of Medical Sciences, Rasht, Iran Nasim Ghorbannejad Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran 2023 12 25 2024 08 12 Thrombotic thrombocytopenic purpura (TTP) is a medical condition characterized by a decreased activity of the ADAMTS13 protease,  responsible for cleaving the von Willebrand factor. It contributes to thrombotic microangiopathy. In this report, we described a case of TTP  followed by significant adverse effects during therapeutic plasma exchange (TPE) treatment. The patient received TPE with a time interval from plasma transfusion. A 30-year-old female was evaluated for headaches and bruises on her arms and legs. Laboratory testing revealed thrombocytopenia and anemia. The identification of thrombocytopenia with severe schistocytosis was verified by the analysis of a peripheral blood smear. After confirming a diagnosis of TTP, TPE was performed as therapy. To avoid the complications arising during the previous TPE sessions, we conducted plasma exchange with albumin followed by FFP injection, with a six-hour interval between them. This strategy successfully alleviated the patient's symptoms. Therapeutic plasma exchange (TPE) with a time interval from plasma transfusion can be successfully used in patients with severe TPE complications. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2145 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2145/1073

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 81 85 EN Esra Cengiz Şanlıurfa Mehmet Akif İnan Education and Training Hospital, Şanlıurfa, Turkiye Muruvvet Aydin Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Ahmet Gunes Ankara Etlik City Hospital, Department of Hematology, Ankara, Turkiye Funda Ceran Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Simten Dagdas Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Gulsum Ozet Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye 2023 08</